JP7684803B2 - 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 - Google Patents

補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 Download PDF

Info

Publication number
JP7684803B2
JP7684803B2 JP2020500686A JP2020500686A JP7684803B2 JP 7684803 B2 JP7684803 B2 JP 7684803B2 JP 2020500686 A JP2020500686 A JP 2020500686A JP 2020500686 A JP2020500686 A JP 2020500686A JP 7684803 B2 JP7684803 B2 JP 7684803B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
modified polypeptide
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020500686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532285A (ja
JP2020532285A5 (enExample
Inventor
パッファー，ブリジット
チャンドラー，ジュリアン
ジェラ，ニミッシュ
エル． シェリダン，ダグラス
ジンダル，シドハース
ピー． タンブリーニ，ポール
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2020532285A publication Critical patent/JP2020532285A/ja
Publication of JP2020532285A5 publication Critical patent/JP2020532285A5/ja
Priority to JP2023085796A priority Critical patent/JP2023120208A/ja
Priority to JP2025044077A priority patent/JP2025118590A/ja
Application granted granted Critical
Publication of JP7684803B2 publication Critical patent/JP7684803B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2020500686A 2017-07-11 2018-07-11 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質 Active JP7684803B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023085796A JP2023120208A (ja) 2017-07-11 2023-05-24 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
JP2025044077A JP2025118590A (ja) 2017-07-11 2025-03-18 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531215P 2017-07-11 2017-07-11
US62/531,215 2017-07-11
PCT/US2018/041661 WO2019014360A1 (en) 2017-07-11 2018-07-11 POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023085796A Division JP2023120208A (ja) 2017-07-11 2023-05-24 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質

Publications (3)

Publication Number Publication Date
JP2020532285A JP2020532285A (ja) 2020-11-12
JP2020532285A5 JP2020532285A5 (enExample) 2021-11-25
JP7684803B2 true JP7684803B2 (ja) 2025-05-28

Family

ID=63036501

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020500686A Active JP7684803B2 (ja) 2017-07-11 2018-07-11 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
JP2023085796A Pending JP2023120208A (ja) 2017-07-11 2023-05-24 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
JP2025044077A Pending JP2025118590A (ja) 2017-07-11 2025-03-18 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023085796A Pending JP2023120208A (ja) 2017-07-11 2023-05-24 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
JP2025044077A Pending JP2025118590A (ja) 2017-07-11 2025-03-18 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質

Country Status (12)

Country Link
US (3) US11498960B2 (enExample)
EP (1) EP3625265A1 (enExample)
JP (3) JP7684803B2 (enExample)
KR (3) KR102806328B1 (enExample)
CN (3) CN111201246B (enExample)
AU (3) AU2018301412B2 (enExample)
BR (1) BR112019028269A2 (enExample)
CA (1) CA3067247A1 (enExample)
CO (1) CO2020000369A2 (enExample)
IL (3) IL271920B2 (enExample)
MX (2) MX2024005946A (enExample)
WO (1) WO2019014360A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201246B (zh) 2017-07-11 2023-10-27 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
WO2020092546A1 (en) * 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
EP3956344A1 (en) * 2019-04-16 2022-02-23 University of Washington Amantadine binding protein
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
WO2021132462A1 (ja) 2019-12-26 2021-07-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 補体ｃ５の発現を抑制する二本鎖リボ核酸を含む医薬組成物
WO2021144962A1 (ja) 2020-01-17 2021-07-22 オリンパス株式会社 発光装置、および駆動装置
JP2023522208A (ja) 2020-04-16 2023-05-29 アシスタンス ピュブリック－オピト ド パリ ウイルスによって引き起こされる補体媒介性障害を処置する方法
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
US20230357442A1 (en) * 2020-10-05 2023-11-09 Alexion Pharmaceuticals, Inc. Methods of treating dermatomyositis
JP2025531719A (ja) * 2022-08-31 2025-09-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 鎌状赤血球症の治療のための融合ポリペプチドの投薬及び投与
CN116731149B (zh) * 2023-06-07 2024-02-27 华中农业大学 草鱼补体活化分子碳末端肽C5a-CP及应用
CN119241699B (zh) * 2024-09-24 2025-11-28 广州康盛生物科技股份有限公司 一种抗人补体c5的单域抗体及其应用
CN121518561A (zh) * 2025-12-24 2026-02-13 北京林业大学 一种PagRAP2.3蛋白点突变及其在植物愈伤再生中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508652A (ja) 2012-02-20 2015-03-23 スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） ヒト補体ｃ５に結合するポリペプチド
JP2016020345A (ja) 2008-08-05 2016-02-04 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
JP2000515002A (ja) 1996-06-27 2000-11-14 フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子
WO1999023221A2 (en) 1997-10-27 1999-05-14 Unilever Plc Multivalent antigen-binding proteins
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
JP4336498B2 (ja) * 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
EP1558647B1 (en) * 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2012254935B2 (en) * 2004-02-12 2014-05-29 Archemix Llc Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN100368022C (zh) 2005-09-20 2008-02-13 中国人民解放军第二军医大学 双重靶向抗肝纤维化药物载体拟糖蛋白纳米粒及其制法
JP4860702B2 (ja) * 2005-10-21 2012-01-25 エフ．ホフマン−ラ ロシュ アーゲー ポリペプチドのリコンビナント発現のための方法
PT2500030E (pt) 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
EP2262831B1 (en) 2008-03-03 2015-01-21 NovelMed Therapeutics, Inc. Anti-properdin antibodies
KR20120105405A (ko) 2009-06-23 2012-09-25 알렉시온 파마슈티칼스, 인코포레이티드 보체 단백질에 결합하는 이중특이적 항체
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
CN102781959A (zh) * 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
CN103003302B (zh) 2010-03-10 2015-09-30 诺沃姆德治疗公司 人源化和嵌合抗-备解素抗体
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
NZ604805A (en) 2010-07-09 2014-09-26 Affibody Ab Polypeptides
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
WO2013006449A2 (en) 2011-07-01 2013-01-10 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
CN104114187A (zh) 2011-12-28 2014-10-22 诺沃姆德治疗公司 去糖基化的人类抗体、其融合蛋白质及用途
CN104870474B (zh) 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
KR102497083B1 (ko) 2013-08-28 2023-02-07 애피바디 에이비 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드
JP6767865B2 (ja) 2013-08-28 2020-10-14 スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） ヒト補体ｃ５に結合する安定なポリペプチド
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CA3049806A1 (en) * 2017-01-30 2018-08-02 Alexion Pharmaceuticals, Inc. Monovalent anti-properdin antibodies and antibody fragments
CN111201246B (zh) 2017-07-11 2023-10-27 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016020345A (ja) 2008-08-05 2016-02-04 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法
JP2015508652A (ja) 2012-02-20 2015-03-23 スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） ヒト補体ｃ５に結合するポリペプチド

Also Published As

Publication number Publication date
JP2023120208A (ja) 2023-08-29
US20250163138A1 (en) 2025-05-22
IL307197B2 (en) 2026-03-01
KR20200026264A (ko) 2020-03-10
AU2025200303A1 (en) 2025-02-13
EP3625265A1 (en) 2020-03-25
KR20250068795A (ko) 2025-05-16
RU2020102910A3 (enExample) 2021-12-02
IL271920B1 (en) 2023-11-01
US11498960B2 (en) 2022-11-15
AU2018301412A9 (en) 2025-08-07
JP2020532285A (ja) 2020-11-12
AU2025200313A1 (en) 2025-02-13
MX2024005945A (es) 2024-06-11
WO2019014360A8 (en) 2019-02-21
IL307197A (en) 2023-11-01
KR102806328B1 (ko) 2025-05-14
WO2019014360A1 (en) 2019-01-17
US12221473B2 (en) 2025-02-11
CN117327187A (zh) 2024-01-02
CO2020000369A2 (es) 2020-01-31
IL271920B2 (en) 2024-03-01
RU2020102910A (ru) 2021-08-11
CN111201246B (zh) 2023-10-27
JP2025118590A (ja) 2025-08-13
IL271920A (en) 2020-02-27
US20200399351A1 (en) 2020-12-24
CA3067247A1 (en) 2019-01-17
CN111201246A (zh) 2020-05-26
MX2024005946A (es) 2024-06-11
CN117327188A (zh) 2024-01-02
AU2018301412A1 (en) 2020-01-30
US20230235033A1 (en) 2023-07-27
IL307197B1 (en) 2025-11-01
KR20250099285A (ko) 2025-07-01
IL324119A (en) 2025-12-01
AU2018301412B2 (en) 2025-08-07
BR112019028269A2 (pt) 2020-07-14

Similar Documents

Publication Publication Date Title
US12221473B2 (en) Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
JP7811315B2 (ja) 補体関連疾患のための融合タンパク質構築物
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
WO2015085847A1 (zh) Pd-1抗体、其抗原结合片段及其医药用途
CN116284377A (zh) 抗人血管生成素3纳米抗体及其应用
CN103906532B (zh) 结合磷酰胆碱（pc）和/或pc结合物的抗体
RU2794359C2 (ru) Полипептиды, которые связываются с компонентом комплемента c5 или сывороточным альбумином, и их белки слияния
HK40106013A (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
HK40106012A (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
WO2024108529A1 (en) Properdin binding protein and use thereof
HK40027205B (zh) 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
US12162931B2 (en) Properdin binding protein and use thereof
HK40027205A (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
BR122025022103A2 (pt) Proteína de fusão, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira isolada, polipeptídeo manipulado, e método de preparação da proteína de fusão

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200309

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230706

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230707

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250516

R150 Certificate of patent or registration of utility model

Ref document number: 7684803

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150